Sangamo Therapeutics, Inc. (0R1D.L)
USD 2.62
(-3.68%)
USD 2.62
(-3.68%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 38.1 Million USD | -11.61% |
| 2022 | 43.1 Million USD | -10.34% |
| 2021 | 48.08 Million USD | 14.24% |
| 2020 | 42.08 Million USD | -5.22% |
| 2019 | 44.4 Million USD | 60.37% |
| 2018 | 27.68 Million USD | 11.93% |
| 2017 | 24.73 Million USD | 527.07% |
| 2016 | 3.94 Million USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | -100.0% |
| 2001 | 285 Thousand USD | 0.0% |
| 2000 | - USD | -100.0% |
| 1999 | 300 Thousand USD | 0.0% |
| 1998 | - USD | 0.0% |
| 1997 | - USD | 0.0% |
| 1996 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 29.09 Million USD | -5.58% |
| 2024 Q1 | 30.81 Million USD | -19.12% |
| 2023 Q2 | 36.37 Million USD | -3.52% |
| 2023 FY | 38.1 Million USD | -11.61% |
| 2023 Q4 | 38.1 Million USD | 8.95% |
| 2023 Q1 | 37.7 Million USD | -12.54% |
| 2023 Q3 | 34.97 Million USD | -3.84% |
| 2022 FY | 43.1 Million USD | -10.34% |
| 2022 Q2 | 41.53 Million USD | -3.0% |
| 2022 Q1 | 42.81 Million USD | -10.95% |
| 2022 Q3 | 39.7 Million USD | -4.39% |
| 2022 Q4 | 43.1 Million USD | 8.57% |
| 2021 Q2 | 37.32 Million USD | -2.95% |
| 2021 Q1 | 38.46 Million USD | -8.61% |
| 2021 FY | 48.08 Million USD | 14.24% |
| 2021 Q4 | 48.08 Million USD | 33.11% |
| 2021 Q3 | 36.12 Million USD | -3.23% |
| 2020 Q1 | 40.19 Million USD | -9.48% |
| 2020 Q3 | 38.25 Million USD | -2.49% |
| 2020 Q4 | 42.08 Million USD | 10.0% |
| 2020 FY | 42.08 Million USD | -5.22% |
| 2020 Q2 | 39.23 Million USD | -2.4% |
| 2019 Q4 | 44.4 Million USD | 9.35% |
| 2019 Q3 | 40.6 Million USD | -2.26% |
| 2019 Q2 | 41.55 Million USD | 212.43% |
| 2019 Q1 | 13.29 Million USD | -51.97% |
| 2019 FY | 44.4 Million USD | 60.37% |
| 2018 Q4 | 27.68 Million USD | 2.83% |
| 2018 FY | 27.68 Million USD | 11.93% |
| 2018 Q3 | 26.92 Million USD | 2.86% |
| 2018 Q2 | 26.18 Million USD | 2.87% |
| 2018 Q1 | 25.44 Million USD | 2.87% |
| 2017 Q3 | 3.87 Million USD | -0.44% |
| 2017 Q2 | 3.88 Million USD | -1.04% |
| 2017 Q4 | 24.73 Million USD | 539.22% |
| 2017 FY | 24.73 Million USD | 527.07% |
| 2017 Q1 | 3.92 Million USD | -0.43% |
| 2016 Q2 | 247 Thousand USD | 15.96% |
| 2016 FY | 3.94 Million USD | 0.0% |
| 2016 Q4 | 3.94 Million USD | 74.87% |
| 2016 Q3 | 2.25 Million USD | 813.36% |
| 2016 Q1 | 213 Thousand USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2002 Q2 | 234 Thousand USD | -56.34% |
| 2002 Q1 | 536 Thousand USD | 88.07% |
| 2002 FY | - USD | -100.0% |
| 2002 Q3 | - USD | -100.0% |
| 2002 Q4 | - USD | 0.0% |
| 2001 FY | 285 Thousand USD | 0.0% |
| 2001 Q4 | 285 Thousand USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2000 Q1 | 12.61 Million USD | 0.0% |
| 2000 FY | - USD | -100.0% |
| 2000 Q2 | - USD | -100.0% |
| 2000 Q4 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 1999 FY | 300 Thousand USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 36.53 Million USD | -4.292% |
| Dynavax Technologies Corporation | 256.91 Million USD | 85.169% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | 8.243% |
| Perrigo Company plc | 4.07 Billion USD | 99.065% |
| Illumina, Inc. | 2.26 Billion USD | 98.315% |
| Thermo Fisher Scientific Inc. | 34.91 Billion USD | 99.891% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -3710.4% |
| Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 99.601% |
| IQVIA Holdings Inc. | 14.23 Billion USD | 99.732% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 78.07% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 98.59% |
| Unity Biotechnology, Inc. | 26.99 Million USD | -41.178% |
| Waters Corporation | 2.35 Billion USD | 98.382% |
| Biogen Inc. | 7.33 Billion USD | 99.481% |
| Evolus, Inc. | 126.54 Million USD | 69.889% |
| Adicet Bio, Inc. | 17.7 Million USD | -115.24% |
| Cara Therapeutics, Inc. | 43.16 Million USD | 11.729% |
| bluebird bio, Inc. | 330.32 Million USD | 88.465% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | 92.956% |
| FibroGen, Inc. | 170.45 Million USD | 77.646% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 98.607% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | -82.453% |
| Homology Medicines, Inc. | 44.05 Million USD | 13.506% |
| Geron Corporation | 85.89 Million USD | 55.641% |
| Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | 98.411% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | 91.438% |
| Myriad Genetics, Inc. | 145 Million USD | 73.721% |
| Viking Therapeutics, Inc. | 1.26 Million USD | -2924.127% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | 66.965% |
| Zoetis Inc. | 6.8 Billion USD | 99.44% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -765.607% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 98.242% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | 96.639% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | 95.286% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -4.903% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | 97.379% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | 34.158% |
| Verastem, Inc. | 41.55 Million USD | 8.309% |
| Nektar Therapeutics | 230.4 Million USD | 83.462% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | 79.555% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -1139.558% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | 97.272% |
| OPKO Health, Inc. | 326.56 Million USD | 88.332% |
| Exelixis, Inc. | 189.94 Million USD | 79.939% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 91.106% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | -25134.437% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 138.4 Million USD | 72.47% |
| Imunon, Inc. | 1.13 Million USD | -3244.53% |
| Blueprint Medicines Corporation | 774.12 Million USD | 95.078% |
| Insmed Incorporated | 1.2 Billion USD | 96.835% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 97.458% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | 33.137% |
| TG Therapeutics, Inc. | 110.79 Million USD | 65.609% |
| Incyte Corporation | 38.28 Million USD | 0.478% |
| Emergent BioSolutions Inc. | 877.5 Million USD | 95.658% |